Surgiphor 1,000mL allows clinicians to remove debris and microorganisms from wounds during powered irrigation procedures.

BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced that it has received CE Mark approval in the European Union for its Revello Vascular Covered Stent. With this approval, BD ...

BD, a leading global medical technology company, and Frazier Healthcare Partners, a leading private equity firm focused exclusively on the healthcare sector, announced a definitive agreement for BD to ...

Medical technology company Becton, Dickinson and Company (NYSE:BDX) reported Q4 CY2025 results beating Wall Street’s revenue expectations , with sales up 1.6% year on year to $5.25 billion. Its ...

Waters Corp. and BD announced a definitive agreement July 14 to combine BD’s Biosciences & Diagnostic Solutions businesses with the Milford, Mass.-based company. The deal is structured as a ...

On February 5, 2025, Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business into an independent entity. The Biosciences and Diagnostic ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

Becton, Dickinson and Co. is increasing its U.S. manufacturing capacity for essential medical devices, including syringes, needles and IV catheters. As part of a $10 million investment in 2024, new ...